{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:11:53Z","timestamp":1789924313731,"version":"4.0.1"},"reference-count":53,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Singapore"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2590401","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:57:57Z","timestamp":1764691077000},"page":"2103-2118","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin\u2019s impact on burden reduction"],"prefix":"10.1080","volume":"28","author":[{"given":"Michael","family":"Kim","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Singapore Pte. Ltd","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"New","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lim","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Lim","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Yi","family":"Wee","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Viswambaram","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijoy","family":"Varghese","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH","place":["Ingelheim am Rhein, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093167"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875"},{"key":"e_1_3_4_4_1","unstructured":"Global burden of disease 2021: findings from the GBD 2021 study. Institute for Health Metrics and Evaluation; 2024 [cited 2025 May 8]. Available from: https:\/\/www.healthdata.org\/research-analysis\/library\/global-burden-disease-2021-findings-gbd-2021-study"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01937-x"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01464-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy596"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.09.003"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/db20211-13"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.017"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006101159"},{"key":"e_1_3_4_13_1","unstructured":"IDF Diabetes Atlas. International Diabetes Foundation; 2025 [cited 2025 May 5]. Available from: https:\/\/diabetesatlas.org\/#:%E2%88%BC:text=Diabetes%20around%20the%20world%20in%202021%3A %2D%20and%20middle%2Dincome%20countries"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007525"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0971"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020378"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.21385"},{"key":"e_1_3_4_20_1","unstructured":"JARDIANCE\u00ae (empagliflozin tablets) for oral use. Boehringer Ingelheim; 2023 [cited 2025 May 8]. Available from: https:\/\/content.boehringer-ingelheim.com\/DAM\/7d9c411c-ec33-4f82-886f-af1e011f35bb\/jardiance-us-pi.pdf"},{"key":"e_1_3_4_21_1","unstructured":"FARXIGA\u00ae (dapagliflozin) tablets for oral use. AstraZeneca Pharmaceuticals; 2024 [cited 2025 Oct 2]. Available from: http:\/\/www.azpicentral.com\/pi.html?product=farxiga"},{"key":"e_1_3_4_22_1","unstructured":"INVOKANA\u00ae (canagliflozin) tablets for oral use. Janssen Pharmaceuticals; 2024 [cited 2025 Oct 2]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVOKANA-pi.pdf"},{"key":"e_1_3_4_23_1","unstructured":"AUSTRALIAN PRODUCT INFORMATION-JARDIANCE\u00ae empagliflozin film-coated tablets. Therapeutic Goods Administration; 2024 [cited 2025 Sep 7]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-08\/auspar-jardiance-240709-pi.pdf"},{"key":"e_1_3_4_24_1","unstructured":"AUSTRALIAN PRODUCT INFORMATION FORXIGA\u00ae (dapagliflozin propanediol monohydrate) tablets. AstraZeneca; 2025 [cited 2025 Sep 7]. Available from: https:\/\/rss.medsinfo.com.au\/ap\/pi.cfm?product=appforxi10425"},{"key":"e_1_3_4_25_1","unstructured":"INVOKANA\u00ae PRODUCT INFORMATION. Therapeutic Goods Administration; 2014 [cited 2025 Sep 7]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-canagliflozin-140303-pi.docx"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13728"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_3_4_28_1","unstructured":"Purchasing power parities (PPP) 2022. Organisation for Economic Co-operation and Development; 2024 [cited 2024 Dec 26]. Available from: https:\/\/www.oecd.org\/en\/data\/indicators\/purchasing-power-parities-ppp.html?oecdcontrol-00b22b2429-var3=2022"},{"key":"e_1_3_4_29_1","unstructured":"PPP conversion factor GDP (LCU per international $)\u2014East Asia & Pacific. World Bank Group; 2023 [cited 2024 Dec 26]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.PPP?locations=Z4"},{"key":"e_1_3_4_30_1","unstructured":"Pharmacoeconomic guidelines for Malaysia. Ministry of Health Malaysia; 2019 [cited 2025 Oct 13]. Available from: https:\/\/pharmacy.moh.gov.my\/sites\/default\/files\/document-upload\/pharmacoeconomic-guidelines-malaysia-malaysia-second-edition-2019-final-page-adjustment.pdf"},{"key":"e_1_3_4_31_1","unstructured":"Philippine HTA methods guide. Department of Health Philippines; 2020 [cited 2025 Oct 13]. Available from: https:\/\/hta.dost.gov.ph\/philippine-hta-methods-guide\/"},{"key":"e_1_3_4_32_1","unstructured":"Guideline for health technology assessment in Thailand updated edition: 2019. Health Systems Research Institute; 2023 [cited 2025 Oct 13]. Available from: https:\/\/kb.hsri.or.th\/dspace\/handle\/11228\/5320?locale-attribute=en"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-083895"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-021-00540-4"},{"key":"e_1_3_4_35_1","unstructured":"Drug and vaccine evaluation methods and process guide. Agency for Care Effectiveness; 2023 [cited 2025 Oct 13]. Available from: https:\/\/www.ace-hta.gov.sg\/resources\/process-methods"},{"key":"e_1_3_4_36_1","unstructured":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Overview and rationale of the economic evaluation. Pharmaceutical Benefits Advisory Committee. [cited 2025 Oct 13]. Available from: https:\/\/pbac.pbs.gov.au\/section-3a\/3a-1-overview-and-rationale-of-economic-evaluation.html"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-022-00721-4"},{"key":"e_1_3_4_38_1","unstructured":"World Economic Outlook. Implied PPP conversion rate. International Monetary Fund; 2025 [cited 2025 Sep 8]. Available from: https:\/\/www.imf.org\/external\/datamapper\/PPPEX@WEO\/OEMDC\/ADVEC\/WEOWORLD\/DA\/IND"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01191-y"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14829"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14810"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100963"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319878371"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0137"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_225_20"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.02.016"},{"key":"e_1_3_4_47_1","unstructured":"Management of type 2 diabetes mellitus 6th ed. Ministry of Health; 2020 [cited 2025 May 8]. Available from: https:\/\/www.acadmed.org.my\/CPGdl\/CPG%20Management%20of%20Type%202%20Diabetes%20Mellitus%20(6th%20Edition)%2020210413.pdf"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01026-2"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.07.016"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.750381"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S266901"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2368990"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.12.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118528"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2590401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:47:32Z","timestamp":1766400452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2590401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2590401"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2590401","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}